Thomas E Witzig

Summary

Affiliation: Mayo Clinic
Country: USA

Publications

  1. ncbi request reprint Elevated serum B-lymphocyte stimulator levels in patients with familial lymphoproliferative disorders
    Anne J Novak
    Division of Hematology and Internal Medicine, Mayo Clinic College of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    J Clin Oncol 24:983-7. 2006
  2. ncbi request reprint Salvage chemotherapy with rituximab DHAP for relapsed non-Hodgkin lymphoma: a phase II trial in the North Central Cancer Treatment Group
    Thomas E Witzig
    Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    Leuk Lymphoma 49:1074-80. 2008
  3. pmc Targeted therapy in lymphoma
    Patrick B Johnston
    Novartis Pharmaceuticals, Florham Park, NJ, USA
    J Hematol Oncol 3:45. 2010
  4. ncbi request reprint Rituximab therapy for patients with newly diagnosed, advanced-stage, follicular grade I non-Hodgkin's lymphoma: a phase II trial in the North Central Cancer Treatment Group
    Thomas E Witzig
    Department of Internal Medicine, Division of Hematology, Mayo Clinic 200 First St SW, Rochester, MN 55905, USA
    J Clin Oncol 23:1103-8. 2005
  5. ncbi request reprint Radioimmunotherapy for patients with relapsed B-cell non-Hodgkin lymphoma
    T E Witzig
    Division of Internal Medicine and Hematology, Mayo Clinic, Rochester 55905, USA
    Cancer Chemother Pharmacol 48:S91-5. 2001
  6. ncbi request reprint Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma
    Thomas E Witzig
    Mayo Clinic, 620 Stabile Building, Rochester, MN 55905, USA
    J Clin Oncol 20:3262-9. 2002
  7. ncbi request reprint Detection of circulating cytokeratin-positive cells in the blood of breast cancer patients using immunomagnetic enrichment and digital microscopy
    Thomas E Witzig
    Department of Laboratory Medicine and Pathology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
    Clin Cancer Res 8:1085-91. 2002
  8. ncbi request reprint Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma
    Thomas E Witzig
    Division of Internal Medicine and Hematology, Nuclear Medicine, Mayo Clinic and Mayo Foundation, 60 Stabile Building, Rochester, MN 55905, USA
    J Clin Oncol 20:2453-63. 2002
  9. ncbi request reprint Heavy chain disease
    Thomas E Witzig
    Division of Hematology, Mayo Clinic and Mayo Foundation, 200 SW First Street, Rochester, MN 55905, USA
    Curr Treat Options Oncol 3:247-54. 2002
  10. ncbi request reprint Yttrium-90-ibritumomab tiuxetan radioimmunotherapy: a new treatment approach for B-cell non-Hodgkin's lymphoma
    Thomas E Witzig
    Mayo Clinic College of Medicine, Division of Internal Medicine and Hematology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
    Drugs Today (Barc) 40:111-9. 2004

Detail Information

Publications144 found, 100 shown here

  1. ncbi request reprint Elevated serum B-lymphocyte stimulator levels in patients with familial lymphoproliferative disorders
    Anne J Novak
    Division of Hematology and Internal Medicine, Mayo Clinic College of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    J Clin Oncol 24:983-7. 2006
    ..Therefore, we sought to establish whether BLyS levels were elevated in patients with B-cell lymphoproliferative disorders and to determine whether elevated BLyS levels correlated with clinical characteristics of the disease...
  2. ncbi request reprint Salvage chemotherapy with rituximab DHAP for relapsed non-Hodgkin lymphoma: a phase II trial in the North Central Cancer Treatment Group
    Thomas E Witzig
    Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    Leuk Lymphoma 49:1074-80. 2008
    ..3 months (95% CI: 5.3-14.0), the median event-free survival (EFS) was 5.3 months (95% CI: 3.9-11.0), and the median overall survival was 30.5 months (95% CI: 17.8-60.6). We conclude that rituximab can be safely added to standard DHAP...
  3. pmc Targeted therapy in lymphoma
    Patrick B Johnston
    Novartis Pharmaceuticals, Florham Park, NJ, USA
    J Hematol Oncol 3:45. 2010
    ..This review will discuss the rationale for and summarize the reported findings of initial and ongoing investigations of mTOR inhibitors and other small molecule targeted therapies in the treatment of lymphoma...
  4. ncbi request reprint Rituximab therapy for patients with newly diagnosed, advanced-stage, follicular grade I non-Hodgkin's lymphoma: a phase II trial in the North Central Cancer Treatment Group
    Thomas E Witzig
    Department of Internal Medicine, Division of Hematology, Mayo Clinic 200 First St SW, Rochester, MN 55905, USA
    J Clin Oncol 23:1103-8. 2005
    ..The goals of this study were to assess the overall response rate (ORR) to rituximab in this patient population and to determine the time-to-progression (TTP) and time-to-subsequent-chemotherapy (TTSC)...
  5. ncbi request reprint Radioimmunotherapy for patients with relapsed B-cell non-Hodgkin lymphoma
    T E Witzig
    Division of Internal Medicine and Hematology, Mayo Clinic, Rochester 55905, USA
    Cancer Chemother Pharmacol 48:S91-5. 2001
    ..Therefore 90Y-ibritumomab tiuxetan radioimmunotherapy is a useful new treatment modality for patients with B cell NHL. Future trials are needed to define the optimal time in the disease course when this modality should be used...
  6. ncbi request reprint Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma
    Thomas E Witzig
    Mayo Clinic, 620 Stabile Building, Rochester, MN 55905, USA
    J Clin Oncol 20:3262-9. 2002
    ..Ibritumomab tiuxetan radioimmunotherapy targets the same antigen as rituximab and has demonstrated efficacy in rituximab-naïve NHL. This study evaluated ibritumomab tiuxetan in the treatment of rituximab-refractory follicular NHL...
  7. ncbi request reprint Detection of circulating cytokeratin-positive cells in the blood of breast cancer patients using immunomagnetic enrichment and digital microscopy
    Thomas E Witzig
    Department of Laboratory Medicine and Pathology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
    Clin Cancer Res 8:1085-91. 2002
    ..To examine the feasibility for identifying and enumerating cytokeratin positive (CK+) cells in the peripheral blood of breast cancer patients...
  8. ncbi request reprint Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma
    Thomas E Witzig
    Division of Internal Medicine and Hematology, Nuclear Medicine, Mayo Clinic and Mayo Foundation, 60 Stabile Building, Rochester, MN 55905, USA
    J Clin Oncol 20:2453-63. 2002
    ....
  9. ncbi request reprint Heavy chain disease
    Thomas E Witzig
    Division of Hematology, Mayo Clinic and Mayo Foundation, 200 SW First Street, Rochester, MN 55905, USA
    Curr Treat Options Oncol 3:247-54. 2002
    ..Patients with MGUS with NHL should be administered chemotherapy. Screening the serum and urine of patients with lymphoplasmacytoid NHL would likely identify more patients with gamma- or mu-HCD...
  10. ncbi request reprint Yttrium-90-ibritumomab tiuxetan radioimmunotherapy: a new treatment approach for B-cell non-Hodgkin's lymphoma
    Thomas E Witzig
    Mayo Clinic College of Medicine, Division of Internal Medicine and Hematology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
    Drugs Today (Barc) 40:111-9. 2004
    ..Future trials will build on these results and determine at what point in the disease course this modality can best be utilized to maximize the benefits to the patient...
  11. ncbi request reprint Radioimmunotherapy for B-cell non-Hodgkin lymphoma
    Thomas E Witzig
    Division of Hematology, Department of Internal Medicine, Mayo Clinic and Mayo Foundation, Stabile 6, 200 SW First Street, Rochester, MN 55905, USA
    Best Pract Res Clin Haematol 19:655-68. 2006
    ..Current trials are testing RIT as initial therapy with rituximab maintenance, as adjuvant therapy after chemotherapy, or in high-dose protocols with stem-cell support...
  12. ncbi request reprint Inhibition of the phosphatidylinositol 3-kinase/mammalian target of rapamycin pathway in hematologic malignancies
    Thomas E Witzig
    Mayo Clinic, Stabile 628, 200 First Street SW, Rochester, MN 55905, USA
    Curr Treat Options Oncol 7:285-94. 2006
    ..Based on results obtained to date, it appears that inhibitors of the PI3-K/mTOR pathway hold promise as single agents and in combination for hematologic malignancies...
  13. ncbi request reprint Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-hodgkin's lymphoma
    Thomas E Witzig
    Division of Internal Medicine and Hematology and the Department of Radiology, Nuclear Medicine, Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    J Clin Oncol 21:1263-70. 2003
    ..This study presents the safety data from 349 patients in five studies of outpatient treatment with (90)Y ibritumomab tiuxetan...
  14. doi request reprint Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's Lymphoma
    Thomas E Witzig
    Mayo Clinic, Rochester, MN 55905, USA
    J Clin Oncol 27:5404-9. 2009
    ..Given its efficacy in a wide range of hematologic malignancies, we conducted a phase II trial (NHL-001) of single-agent lenalidomide in indolent non-Hodgkin's lymphoma (NHL)...
  15. ncbi request reprint Phase III, randomized, double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy
    Thomas E Witzig
    Department of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    J Clin Oncol 23:2606-17. 2005
    ..To determine whether weekly epoetin alfa could improve hemoglobin (HgB) levels, reduce RBC transfusions, and improve quality of life (QOL) in patients with advanced cancer and with anemia after receiving myelosuppressive chemotherapy...
  16. ncbi request reprint Current treatment approaches for mantle-cell lymphoma
    Thomas E Witzig
    Mayo Clinic, Stabile 628, 200 First St SW, Rochester, MN 55905, USA
    J Clin Oncol 23:6409-14. 2005
    ..Studies integrating these novel agents earlier in the disease course or in combination with each other will hopefully produce more durable responses with less toxicity...
  17. ncbi request reprint Prognostic value of proliferation, apoptosis, defective DNA mismatch repair, and p53 overexpression in patients with resected Dukes' B2 or C colon cancer: a North Central Cancer Treatment Group Study
    Megan M Garrity
    Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    J Clin Oncol 22:1572-82. 2004
    ..This study investigated the prognostic significance of TUNEL, bcl-2, p53, proliferation marker Ki-67 and DNA mismatch repair (MMR) status in patients with Dukes' stage B2 and C colorectal adenocarcinomas...
  18. ncbi request reprint Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma
    Thomas E Witzig
    Mayo Clinic College of Medicine, Stabile 628, 200 First St SW, Rochester, MN 55905, USA
    J Clin Oncol 23:5347-56. 2005
    ..This study tested whether temsirolimus (previously known as CCI-779), an inhibitor of the mammalian target of rapamycin kinase that regulates cyclin D1 translation, could produce tumor responses in patients with MCL...
  19. pmc A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma
    T E Witzig
    Division of Hematology, Department of Medicine, Mayo Clinic College of Medicine and Mayo Foundation, Rochester, MN 55905, USA
    Leukemia 25:341-7. 2011
    ..Everolimus has single-agent activity in relapsed/refractory aggressive NHL and provides proof-of-concept that targeting the mTOR pathway is clinically relevant...
  20. pmc Signal transduction inhibitor therapy for lymphoma
    Thomas E Witzig
    Division of Hematology, Department of Internal Medicine, Mayo Clinic College of Medicine and Mayo Foundation, Rochester, MN 55905, USA
    Hematology Am Soc Hematol Educ Program 2010:265-70. 2010
    ..The goal is to provide the hematologist/oncologist background information on these new agents and understand their current and potential role in the management of patients...
  21. ncbi request reprint The role of adhesion receptors in the pathogenesis of multiple myeloma
    T E Witzig
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA
    Hematol Oncol Clin North Am 13:1127-43. 1999
    ..Future research is needed to delineate the signaling pathways used by the plasma cell after the adhesion receptor binds to its ligands. This information should help in designing more effective therapy for this fatal disease...
  22. ncbi request reprint Syndecan-1 expression on malignant cells from the blood and marrow of patients with plasma cell proliferative disorders and B-cell chronic lymphocytic leukemia
    T E Witzig
    Division of Internal Medicine and Hematology, Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    Leuk Lymphoma 31:167-75. 1998
    ..In addition, syndecan-1 is present on the less mature (CD45+) PC, and there is heterogeneity of expression within and between patients. The relevance of the bFGF bound to myeloma cells via syndecan-1 remains to be elucidated...
  23. ncbi request reprint Treatment of benign orbital pseudolymphomas with the monoclonal anti-CD20 antibody rituximab
    Thomas E Witzig
    Department of Internal Medicine, Division of Hematology, College of Medicine, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Mayo Clin Proc 82:692-9. 2007
    ..To report the results of treating patients with orbital pseudolymphomas with the anti-CD20 monoclonal antibody rituximab...
  24. ncbi request reprint A phase I trial of high dose ProMACE-CytaBOM with granulocyte colony stimulating factor for patients with non-Hodgkin's lymphoma
    T E Witzig
    Division of Internal Medicine and Hematology, Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    Leuk Lymphoma 28:307-14. 1998
    ..This higher dose ProMACECytaBOM regimen can be given to older adult patients in an outpatient setting. Phase III studies would be required to determine if it produces a superior overall survival compared to other regimens...
  25. ncbi request reprint A prospective study of CD38/45 flow cytometry and immunofluorescence microscopy to detect blood plasma cells in patients with plasma cell proliferative disorders
    T E Witzig
    Department of Internal Medicine, Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    Leuk Lymphoma 38:345-50. 2000
    ..The prognostic implications of a positive FC screen but a negative IM will require long-term patient follow-up...
  26. doi request reprint An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma
    T E Witzig
    Department of Medicine, Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Ann Oncol 22:1622-7. 2011
    ....
  27. pmc Multi-institutional phase 2 study of the farnesyltransferase inhibitor tipifarnib (R115777) in patients with relapsed and refractory lymphomas
    Thomas E Witzig
    Division of Hematology, Department of Medicine, Mayo Clinic College of Medicine and Mayo Foundation, Rochester, MN, USA
    Blood 118:4882-9. 2011
    ..In view of its excellent toxicity profile and novel mechanism of action, further studies in combination with other agents appear warranted. This trial is registered at www.clinicaltrials.gov as #NCT00082888...
  28. ncbi request reprint Combination therapy with thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma not undergoing upfront autologous stem cell transplantation: a phase II trial
    David Dingli
    Division of Hematology, Department of Internal Medicine, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    Haematologica 90:1650-4. 2005
    ..We present the first data on the outcome of patients with newly diagnosed multiple myeloma treated with Thal/Dex who did not undergo upfront ASCT...
  29. pmc Comprehensive analysis of tumor microenvironment cytokines in Waldenstrom macroglobulinemia identifies CCL5 as a novel modulator of IL-6 activity
    Sherine F Elsawa
    Schulze Center for Novel Therapeutics, Mayo Clinic, Rochester, MN 55905, USA
    Blood 118:5540-9. 2011
    ..Thus, together these results define a novel signaling network in the WM tumor microenvironment controlling IgM secretion and suggest CCL5 as a potential target for the treatment of this disease...
  30. pmc Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients
    Francesca Gay
    Department of Internal Medicine, Division of Hematology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Blood 115:1343-50. 2010
    ..3% vs 9.2%, P = .058) and peripheral neuropathy (10.4% vs 0.9%, P < .001). Len/dex appears well-tolerated and more effective than thal/dex. Randomized trials are needed to confirm these results...
  31. ncbi request reprint Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma
    Martha Q Lacy
    Division of Hematology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Mayo Clin Proc 82:1179-84. 2007
    ..To determine the long-term effects of a combined regimen of lenalidomide and dexamethasone (Rev-Dex) on time to progression, progression-free survival, and overall survival (OS) in patients with multiple myeloma...
  32. pmc Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone
    Prashant Kapoor
    Department of Internal Medicine, Division of Hematology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    Blood 114:518-21. 2009
    ..These results need confirmation in larger, prospectively designed studies...
  33. pmc Elevated serum free light chains are associated with event-free and overall survival in two independent cohorts of patients with diffuse large B-cell lymphoma
    Matthew J Maurer
    Mayo Clinic College of Medicine and Mayo Foundation, Rochester, MN 55905, USA
    J Clin Oncol 29:1620-6. 2011
    ..This assay has prognostic value in plasma cell proliferative disorders. There are limited data on serum FLC in B-cell malignancies...
  34. pmc Flow cytometric detection of circulating myeloma cells before transplantation in patients with multiple myeloma: a simple risk stratification system
    David Dingli
    Division of Hematology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    Blood 107:3384-8. 2006
    ..4, and 6.5 months, respectively. CMCs at the time of ASCT is an independent prognostic factor and in combination with cytogenetics provides a powerful scoring system that stratifies patients and guides management...
  35. ncbi request reprint A phase I trial of immunostimulatory CpG 7909 oligodeoxynucleotide and 90 yttrium ibritumomab tiuxetan radioimmunotherapy for relapsed B-cell non-Hodgkin lymphoma
    Thomas E Witzig
    Department of Internal Medicine, Division of Hematology, Mayo Clinic College of Medicine and Mayo Foundation, Rochester, Minnesota
    Am J Hematol 88:589-93. 2013
    ..CpG 7909 at a dose of 0.48 mg/kg is safe with standard RIT and produces a high CR rate and long DR; these results warrant confirmation...
  36. pmc Inhibition of histone deacetylase overcomes rapamycin-mediated resistance in diffuse large B-cell lymphoma by inhibiting Akt signaling through mTORC2
    Mamta Gupta
    Division of Hematology and Department of Oncology, Mayo Clinic, Rochester, MN, USA
    Blood 114:2926-35. 2009
    ..These results provide a mechanistic rationale for a clinical trial of a combination of HDI and mTOR inhibitors for DLBCL...
  37. pmc Circulating plasma cells detected by flow cytometry as a predictor of survival in 302 patients with newly diagnosed multiple myeloma
    Grzegorz S Nowakowski
    Division of Hematology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Blood 106:2276-9. 2005
    ..We conclude that the number of circulating PCs measured by flow cytometry in patients with newly diagnosed MM is an independent predictor of survival...
  38. pmc Elevated pretreatment serum levels of interferon-inducible protein-10 (CXCL10) predict disease relapse and prognosis in diffuse large B-cell lymphoma patients
    Stephen M Ansell
    Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Am J Hematol 87:865-9. 2012
    ..99, P = 0.009, overall survival-HR 1.93, P = 0.021). Elevated pretreatment serum IP-10 levels are therefore associated with an increased likelihood of disease relapse and an inferior survival in patients with DLBCL...
  39. ncbi request reprint Radiation dosimetry results from a Phase II trial of ibritumomab tiuxetan (Zevalin) radioimmunotherapy for patients with non-Hodgkin's lymphoma and mild thrombocytopenia
    Gregory A Wiseman
    Mayo Clinic, Rochester, MN 55905, USA
    Cancer Biother Radiopharm 18:165-78. 2003
    ..These correlations were not consistent across the total patient population, and therefore, could not be exploited to predict hematologic toxicity...
  40. ncbi request reprint A phase II trial of imatinib in patients with refractory/relapsed myeloma
    Angela Dispenzieri
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN, USA
    Leuk Lymphoma 47:39-42. 2006
    ..Patients ended treatment due to progressive disease (18 patients), death (3) and other (2). The data suggest that imatinib is not an active agent in patients with relapsed or refractory multiple myeloma...
  41. doi request reprint Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple myeloma: results from a phase 2 trial
    Shaji K Kumar
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    Am J Hematol 86:640-5. 2011
    ..CRd is an effective and well-tolerated regimen for upfront therapy of MM with high response rates and excellent 2-year OS, and is suitable for long-term therapy...
  42. pmc Long-term results of single-agent thalidomide as initial therapy for asymptomatic (smoldering or indolent) myeloma
    Kristen Detweiler-Short
    Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Am J Hematol 85:737-40. 2010
    ..Grade 3-4 nonhematologic adverse events were noted in 55% of patients. Randomized trials are needed to determine the role of early therapy in SMM...
  43. ncbi request reprint The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis
    Angela Dispenzieri
    Department of Biostatistics, Mayo Clinic, Rochester, MN 55905, USA
    Blood 109:465-70. 2007
    ..In AL patients, we saw limited activity of single-agent lenalidomide, but significant activity of the combination with dexamethasone, which warrants further investigation...
  44. pmc Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1{beta}-induced interleukin 6 production and the myeloma proliferative component
    John A Lust
    Division of Hematology, Mayo Clinic, Rochester, MN 55905
    Mayo Clin Proc 84:114-22. 2009
    ..To conduct in vitro studies as well as a phase 2 clinical trial in patients with smoldering or indolent multiple myeloma to determine if interleukin 1 (IL-1) inhibitors can delay or prevent active myeloma...
  45. ncbi request reprint Absolute lymphocyte count predicts therapeutic efficacy of rituximab therapy in follicular lymphomas
    Deepti Behl
    Division of Hematology Department Medicine, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    Br J Haematol 137:409-15. 2007
    ..89 x 10(9)/l (5/39, 13%) (P < 0.0001). Multivariate analysis showed ALC to be an independent predictor for TTP. This study supports our hypothesis that a higher ALC predicts longer TTP following rituximab therapy...
  46. doi request reprint Trends and outcomes of modern staging of solitary plasmacytoma of bone
    Rahma Warsame
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA
    Am J Hematol 87:647-51. 2012
    ..The use of modern testing is imperative to characterize a patient's risk for progression. PET/CT plays an important role in the diagnostic work-up...
  47. doi request reprint Peripheral blood lymphocyte/monocyte ratio at diagnosis and survival in nodular lymphocyte-predominant Hodgkin lymphoma
    Luis F Porrata
    Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Br J Haematol 157:321-30. 2012
    ..ALC/AMC-DX is a low cost, already standarized, biomarker to predict clinical outcomes in NLPHL...
  48. pmc Risk of non-Hodgkin lymphoma in association with germline variation in complement genes
    James R Cerhan
    Division of Epidemiology, Department of Health Sciences Research, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    Br J Haematol 145:614-23. 2009
    ..015; OR = 0.68; 95% 0.56-0.84) remained noteworthy. Associations were similar for the common NHL subtypes. In summary, we provide evidence for a role of genetic variation in complement genes, particularly C5 and C9, and NHL risk...
  49. pmc Diagnosis and management of Waldenström macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines
    Stephen M Ansell
    Division of Hematology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Mayo Clin Proc 85:824-33. 2010
    ..Autologous stem cell transplant should be considered in all eligible patients with relapsed disease...
  50. ncbi request reprint Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study
    Angela Dispenzieri
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Blood 103:3960-3. 2004
    ..Outside a randomized clinical trial, these results present the strongest data supporting the role of PBSCT in selected patients with AL...
  51. ncbi request reprint Review of 1027 patients with newly diagnosed multiple myeloma
    Robert A Kyle
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, Minn 55905, USA
    Mayo Clin Proc 78:21-33. 2003
    ..To determine the clinical and laboratory features of newly diagnosed multiple myeloma...
  52. pmc Monocytes promote tumor cell survival in T-cell lymphoproliferative disorders and are impaired in their ability to differentiate into mature dendritic cells
    Ryan A Wilcox
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Blood 114:2936-44. 2009
    ..Collectively, the data presented demonstrate a previously undescribed role for monocytes in T-cell lymphoproliferative disorders...
  53. ncbi request reprint Subsequent chemotherapy regimens are well tolerated after radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for non-Hodgkin's lymphoma
    Stephen M Ansell
    Divisions of Hematology and Nuclear Medicine, Mayo Clinic, Rochester, MN 55905, USA
    J Clin Oncol 20:3885-90. 2002
    ..The goal of this analysis was to evaluate the therapy given to patients who relapsed after 90Y ibritumomab tiuxetan...
  54. ncbi request reprint Response rate, durability of response, and survival after thalidomide therapy for relapsed multiple myeloma
    Shaji Kumar
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, Minn 55905, USA
    Mayo Clin Proc 78:34-9. 2003
    ..To assess response rate, duration of response, progression-free survival, and toxicity of thalidomide in patients with relapsed multiple myeloma...
  55. pmc Expression of Myc, but not pSTAT3, is an adverse prognostic factor for diffuse large B-cell lymphoma treated with epratuzumab/R-CHOP
    Mamta Gupta
    Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Blood 120:4400-6. 2012
    ..05), G-CSF (P = .03), and TNF-α (P = .04). pSTAT3 IHC in DLBCL tumors has the potential to identify patients for STAT3 pathway-directed therapy; Myc IHC is a potential marker for inferior EFS in GCB patients...
  56. ncbi request reprint Yttrium 90 ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory low-grade non-Hodgkin's lymphoma
    Leo I Gordon
    Division of Hematology Oncology, Department of Medicine, Northwestern University Medical School and The Robert H Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL 60611 2927, USA
    Semin Oncol 29:87-92. 2002
    ..These targeted approaches to the treatment of malignancy, and lymphoma in particular, hold great promise...
  57. ncbi request reprint Prognostic impact of microsatellite instability and DNA ploidy in human colon carcinoma patients
    Frank A Sinicrope
    Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Gastroenterology 131:729-37. 2006
    ..Given that high-frequency MSI (MSI-H) and diploidy are correlated, we determined whether they are independent prognostic variables...
  58. ncbi request reprint Effectiveness of second line salvage chemotherapy with ifosfamide, carboplatin, and etoposide in patients with relapsed diffuse large B-cell lymphoma not responding to cis-platinum, cytosine arabinoside, and dexamethasone
    Lijo Simpson
    Division of Hematology, Department of Medicine, Rochester, MN, USA
    Leuk Lymphoma 48:1332-7. 2007
    ..Patients with progressive disease on DHAP should be considered for alternative salvage regimens or experimental therapy...
  59. ncbi request reprint Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial
    Gregory A Wiseman
    Division of Nuclear Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Blood 99:4336-42. 2002
    ..The incidence of grade 4 neutropenia, thrombocytopenia, and anemia was 33%, 13%, and 3%, respectively. Reduced-dose ibritumomab tiuxetan is safe and well tolerated and has significant clinical activity in this patient population...
  60. ncbi request reprint Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan
    Thomas E Witzig
    Department of Internal Medicine, Division of Hematology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer 109:1804-10. 2007
    ..Radioimmunotherapy with radiolabeled monoclonal antibodies to CD20 produces a high response rate in patients with recurring non-Hodgkin lymphoma (NHL), but the durability of those remissions is not well defined...
  61. ncbi request reprint Prognostic value of circulating plasma cells in monoclonal gammopathy of undetermined significance
    Shaji Kumar
    Department of Internal Medicine, Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    J Clin Oncol 23:5668-74. 2005
    ..Identification of patients with MGUS at high risk of progression will allow development of preventive strategies. We studied the prognostic value of circulating plasma cells (PCs) in patients with MGUS to predict progression...
  62. ncbi request reprint Prognostic value of angiogenesis in solitary bone plasmacytoma
    Shaji Kumar
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Blood 101:1715-7. 2003
    ..02). Angiogenesis is increased in solitary plasmacytoma and is a significant predictor of progression to myeloma and provides further evidence of its importance in the pathogenesis of myeloma...
  63. pmc Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosis
    Angela Dispenzieri
    Division of Hematology, Department of Medicine, Mayo Clinic Rochester, Rochester, NY, USA
    Blood 119:5397-404. 2012
    ..We conclude that pomalidomide appears to be a valuable drug covering an unmet clinical need in patients with previously treated AL. The trial is registered at www.clinicaltrials.gov as NCT00558896...
  64. ncbi request reprint Randomized phase II study of interleukin-12 in combination with rituximab in previously treated non-Hodgkin's lymphoma patients
    Stephen M Ansell
    Division of Hematology, Mayo Clinic, Rochester, Minnesota and North Central Cancer Treatment Group, Rochester, Minnesota 55905, USA
    Clin Cancer Res 12:6056-63. 2006
    ..This phase II study was done to determine the efficacy and toxicity of IL-12 in combination with rituximab in patients with B-cell non-Hodgkin's lymphoma (NHL)...
  65. pmc B-lymphocyte stimulator (BLyS) stimulates immunoglobulin production and malignant B-cell growth in Waldenstrom macroglobulinemia
    Sherine F Elsawa
    Division of Hematology and Internal Medicine, Mayo Clinic, 200 First St SW, Rochester, MN 55905
    Blood 107:2882-8. 2006
    ..Furthermore, BLyS was found to increase the viability and proliferation of malignant B cells from WM patients. Due to the role of BLyS in WM, strategies to inhibit BLyS may potentially have therapeutic efficacy in these patients...
  66. pmc A proliferation-inducing ligand mediates follicular lymphoma B-cell proliferation and cyclin D1 expression through phosphatidylinositol 3-kinase-regulated mammalian target of rapamycin activation
    Mamta Gupta
    Mayo Clinic, Rochester, MN 55905, USA
    Blood 113:5206-16. 2009
    ..These studies are the first to characterize APRIL-TACI-specific signaling and suggest a role for this ligand-receptor pair in FL B-cell growth...
  67. ncbi request reprint Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis
    Angela Dispenzieri
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    J Clin Oncol 22:3751-7. 2004
    ..Others have reported that N-terminal pro-brain natriuretic peptide (NT-proBNP) is a valuable prognostic marker. We sought to develop a staging system for patients with AL...
  68. pmc Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines
    Shaji K Kumar
    Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Mayo Clin Proc 84:1095-110. 2009
    ..This set of recommendations represents such an effort-the development of a set of consensus guidelines by a group of experts to manage patients with newly diagnosed disease based on an interpretation of the best available evidence...
  69. doi request reprint A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma
    Patrick B Johnston
    Division of Hematology, Department of Medicine, Mayo Clinic College of Medicine and Mayo Foundation, Rochester, Minnesota 55905, USA
    Am J Hematol 85:320-4. 2010
    ..Four patients experienced a Grade 3 or higher pulmonary toxicity. Everolimus has single-agent activity in relapsed/refractory HL and provides proof-of-concept that targeting the mTOR pathway in HL is clinically relevant...
  70. doi request reprint Clarithromycin (Biaxin)-lenalidomide-low-dose dexamethasone (BiRd) versus lenalidomide-low-dose dexamethasone (Rd) for newly diagnosed myeloma
    Francesca Gay
    Division of Hematology, Department of Internal Medicine, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    Am J Hematol 85:664-9. 2010
    ..5% vs. 4.2%, P = 0.129) were higher with Rd. Results of this case-matched analysis suggest that there is significant additive value when clarithromycin is added to Rd. Randomized phase III trials are needed to confirm these results...
  71. ncbi request reprint Bone marrow angiogenesis in multiple myeloma: effect of therapy
    Shaji Kumar
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Br J Haematol 119:665-71. 2002
    ..We conclude that the degree of bone marrow angiogenesis is a prognostic marker in patients with multiple myeloma and does not decrease significantly after therapy...
  72. pmc Vitamin D insufficiency and prognosis in non-Hodgkin's lymphoma
    Matthew T Drake
    College of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    J Clin Oncol 28:4191-8. 2010
    ..Recent data also suggest that vitamin D insufficiency is related to inferior prognosis in some cancers, although there are no data for NHL...
  73. ncbi request reprint Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin's lymphoma
    William G Martin
    Division of Hematology and Internal Medicine, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    J Clin Oncol 23:7614-20. 2005
    ..We reviewed our experience with BPT in HL to better delineate outcome and appropriate treatment in these patients...
  74. ncbi request reprint CD45 expression by bone marrow plasma cells in multiple myeloma: clinical and biological correlations
    S Kumar
    Division of Hematology, Department of Internal Medicine, Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    Leukemia 19:1466-70. 2005
    ..07). The expression of CD138, CD56 and CD54 were higher among the CD45- PCs. This study demonstrates important biological correlates of CD45 expression on myeloma cells...
  75. ncbi request reprint Treatment of diuretic refractory pleural effusions with bevacizumab in four patients with primary systemic amyloidosis
    Robert J Hoyer
    Division of Hematology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Am J Hematol 82:409-13. 2007
    ..Additional studies are needed to further define the role of bevacizumab in the management of this group of patients...
  76. ncbi request reprint Plasma levels of tumour necrosis factor alpha and interleukin-6 predict progression-free survival following thalidomide therapy in patients with previously untreated multiple myeloma
    Michael A Thompson
    Division of Hematology, Mayo Clinic and Mayo Foundation, Rochester, MN, USA
    Br J Haematol 123:305-8. 2003
    ..01; IL-6, 24% versus 70% at 2 years, P = 0.01). None of the other parameters predicted response or PFS, and no significant changes in cytokine levels occurred with therapy...
  77. ncbi request reprint Expression of CD52 on plasma cells in plasma cell proliferative disorders
    Shaji Kumar
    Department of Internal Medicine, Division of Hematology, Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    Blood 102:1075-7. 2003
    ..Clinical trials are warranted in these diseases to learn the therapeutic benefit of anti-CD52 immunotherapy...
  78. ncbi request reprint Efficacy and safety of 90Y ibritumomab tiuxetan (Zevalin) radioimmunotherapy for non-Hodgkin's lymphoma
    Thomas E Witzig
    Department of Hematology Oncology, Mayo Clinic, Rochester, MN 55905, USA
    Semin Oncol 30:11-6. 2003
    ..The use of (90)Y ibritumomab tiuxetan does not preclude subsequent therapy with other conventional treatment options...
  79. pmc CDDO-imidazolide mediated inhibition of malignant cell growth in Waldenström macroglobulinemia
    Sherine F Elsawa
    Division of Hematology and Internal Medicine, Mayo Clinic College of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Leuk Res 32:1895-902. 2008
    ..CDDO-Im also inhibited survival pathways that have been shown to be important in WM. Overall, our data suggest that ST are likely to provide therapeutic efficacy for WM patients...
  80. ncbi request reprint Radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for patients with relapsed CD20+ B-cell non-Hodgkin's lymphoma
    Thierry Alcindor
    Department of Internal Medicine, Division of Hematology, Mayo Clinic and Mayo Foundation, 200 First Street, Rochester, MN 55905, USA
    Curr Treat Options Oncol 3:275-82. 2002
    ..The outcome of these studies will be helpful in deciding how best to integrate this new modality into the treatment paradigm of NHL...
  81. doi request reprint Lymphopenia assessed during routine follow-up after immunochemotherapy (R-CHOP) is a risk factor for predicting relapse in patients with diffuse large B-cell lymphoma
    L F Porrata
    Division of Hematology, Department of Medicine, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Leukemia 24:1343-9. 2010
    ..96 x 10(9)/l (N=46) (P<0.0001). This study suggests that lymphopenia measured by ALC can be used as a marker to assess risk of DLBCL relapse during routine follow-up after standard chemotherapy...
  82. ncbi request reprint Promising preclinical activity of 2-methoxyestradiol in multiple myeloma
    David Dingli
    Molecular Medicine Program, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA
    Clin Cancer Res 8:3948-54. 2002
    ..There are limited treatment options for patients with multiple myeloma (MM) who relapse after high-dose therapy and stem cell transplantation. We studied the preclinical activity of 2ME2 as a therapeutic agent for myeloma...
  83. pmc Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment Group
    Stephen M Ansell
    Division of Hematology, Mayo Clinic College of Medicine and Mayo Foundation, Rochester, Minnesota, USA
    Cancer 113:508-14. 2008
    ..The objective of this study was to test a low dose of (25 mg weekly) of the mammalian target of rapamycin kinase inhibitor temsirolimus for patients with relapsed mantle cell lymphoma (MCL)...
  84. ncbi request reprint Cytokine and chemokine profiles in multiple myeloma; significance of stromal interaction and correlation of IL-8 production with disease progression
    Michael Kline
    Division of Hematology and Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Leuk Res 31:591-8. 2007
    ..We conclude that stromal cell IL-8 production parallels MM disease activity, is IL-1beta induced, and correlates with bone marrow angiogenesis...
  85. ncbi request reprint Expression of BLyS and its receptors in B-cell non-Hodgkin lymphoma: correlation with disease activity and patient outcome
    Anne J Novak
    Division of Hematology and Internal Medicine, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Blood 104:2247-53. 2004
    ..In summary, we found that BLyS and its receptors represent a potentially important therapeutic target in B-cell lymphoma...
  86. ncbi request reprint Therapeutic options in patients with lymphoma and severe liver dysfunction
    Irene M Ghobrial
    Division of Hematology and Internal Medicine, Mayo Clinic College of Medicine, 200 First St SW, Rochester, MN 55905, USA
    Mayo Clin Proc 79:169-75. 2004
    ....
  87. ncbi request reprint High-dose therapy and autologous stem cell transplantation for multiple myeloma poorly responsive to initial therapy
    S Kumar
    Division of Hematology, Department of Medicine, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    Bone Marrow Transplant 34:161-7. 2004
    ..65). The lack of response to initial induction therapy does not appear to preclude a good response to SCT. We recommend that patients with primary refractory MM be offered early SCT...
  88. ncbi request reprint Prognostic value of bone marrow angiogenesis in patients with multiple myeloma undergoing high-dose therapy
    S Kumar
    Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Bone Marrow Transplant 34:235-9. 2004
    ..007. BM MVD at the time of initial diagnosis is an important prognostic factor for OS and PFS in patients undergoing autologous transplantation as frontline therapy for myeloma...
  89. doi request reprint Treatment recommendations for radioimmunotherapy in follicular lymphoma: a consensus conference report
    Thomas E Witzig
    Mayo Clinic, Rochester, MN 55905, USA
    Leuk Lymphoma 52:1188-99. 2011
    ..Maximizing RIT benefit requires healthcare providers to utilize algorithms assisting with treatment decisions...
  90. ncbi request reprint Yttrium-90 (90Y) ibritumomab tiuxetan (Zevalin) induces long-term durable responses in patients with relapsed or refractory B-Cell non-Hodgkin's lymphoma
    Gregory A Wiseman
    Mayo Clinic, Rochester, MN, USA
    Cancer Biother Radiopharm 20:185-8. 2005
    ..This retrospective analysis was conducted to determine the number of patients achieving long-term durable responses with (90)Y ibritumomab tiuxetan treatment...
  91. doi request reprint Phase I clinical study of atacicept in patients with relapsed and refractory B-cell non-Hodgkin's lymphoma
    Stephen M Ansell
    Division of Hematology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Clin Cancer Res 14:1105-10. 2008
    ..Atacicept (TACI-Ig), a recombinant fusion protein that inhibits both B-lymphocyte stimulator and a proliferation-inducing ligand, may be a novel treatment for B-cell malignancies...
  92. ncbi request reprint Antilymphoma treatments given subsequent to Yttrium 90 ibritumomab tiuxetan are feasible in patients with progressive non-Hodgkin's lymphoma: a review of the literature
    Stephen M Ansell
    Division of Hematology Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Clin Lymphoma 5:202-4. 2004
    ....
  93. ncbi request reprint Subcutaneous interleukin-4 (IL-4) for relapsed and resistant non-Hodgkin lymphoma: a phase II trial in the North Central Cancer Treatment Group, NCCTG 91-78-51
    David M Kurtz
    Mayo Clinic and Mayo Foundation, Rochester, MN, USA
    Leuk Lymphoma 48:1290-8. 2007
    ....
  94. ncbi request reprint Absolute lymphocyte count at the time of first relapse predicts survival in patients with diffuse large B-cell lymphoma
    Luis F Porrata
    Division of Hematology Department of Medicine, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Am J Hematol 84:93-7. 2009
    ..ALC-R was an independent prognostic factor for OS [RR = 0.4, P < 0.01] and PFS [RR = 0.5, P < 0.005]. ALC-R predicts survival suggesting that host immunity is an important variable predicting survival in first relapsed DLBCL...
  95. ncbi request reprint Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation
    Angela Dispenzieri
    Division of Hematology and Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Blood 104:1881-7. 2004
    ..Using this system, 49%, 38%, and 13% of patients were in stage I, stage II, and stage III, respectively. Determining levels of circulating biomarkers may be the most powerful tool for staging patients with AL undergoing PBSCT...
  96. pmc The treatment of recurrent/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL) with everolimus results in clinical responses and mobilization of CLL cells into the circulation
    Clive S Zent
    Division of Hematology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer 116:2201-7. 2010
    ..The aim of this study was to learn if inhibition of the mammalian target of rapamycin (mTOR) would produce tumor responses...
  97. ncbi request reprint Hormone replacement therapy and risk of non-hodgkin lymphoma and chronic lymphocytic leukemia
    James R Cerhan
    Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer Epidemiol Biomarkers Prev 11:1466-71. 2002
    ..For diffuse NHL, 64% of the cases were nodal, and there was no association of HRT with either nodal or extra-nodal sites. These data suggest that HRT is a risk factor for follicular NHL but not for diffuse or small lymphocyte NHL or CLL...
  98. doi request reprint Clinical outcome of immunoglobulin light chain amyloidosis affecting the kidney
    Morie A Gertz
    Division of Hematology, Mayo Clinic, Rochester, MN, USA
    Nephrol Dial Transplant 24:3132-7. 2009
    ..The kidney is affected by immunoglobulin light chain amyloidosis (AL) in more than 50% of patients who present with the disease, but long-term predictors for and outcomes after renal replacement therapy are not well described...
  99. doi request reprint Long-term risk of myelodysplasia in melphalan-treated patients with immunoglobulin light-chain amyloidosis
    Morie A Gertz
    Department of Hematology, Mayo Clinic, 200 First Street SW, Rochester MN, 55905, USA
    Haematologica 93:1402-6. 2008
    ..The actuarial risk of myelodysplasia development at ten years was 18%. As the survival of patients with plasma cell disorders improves, myelodysplasia may be a more common cause of morbidity and mortality for this group...
  100. ncbi request reprint Microsatellite instability accounts for tumor site-related differences in clinicopathologic variables and prognosis in human colon cancers
    Frank A Sinicrope
    Mayo Clinic and Mayo College of Medicine, Rochester, Minnesota 55905, USA
    Am J Gastroenterol 101:2818-25. 2006
    ..Given that 15-20% of sporadic colon cancers are MSI-H, we determined whether tumor site-specific differences in clinicopathological variables, biomarkers, and prognosis are due to inclusion of MSI-H cases...
  101. doi request reprint Improvement of cast nephropathy with plasma exchange depends on the diagnosis and on reduction of serum free light chains
    N Leung
    Division of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota 55905, USA
    Kidney Int 73:1282-8. 2008
    ..We found that the relationship between renal recovery and free light chain reduction was present only in patients with biopsy proven cast nephropathy showing the importance of extracorporeal light chain removal in this disease...